SCHEDULE 13D/A: Novo Holdings A/S Updates Galecto, Inc. Stake to 7.6% Following Reverse Stock Split

Novo Holdings A/S has filed an amendment to its Schedule 13D, reporting a 7.6% beneficial ownership in Galecto, Inc. after a 1-for-25 reverse stock split and an increase in outstanding shares.

Summary

• Novo Holdings A/S, a Danish investment firm wholly owned by Novo Nordisk Foundation, filed an Amendment No. 3 to Schedule 13D regarding its beneficial ownership in Galecto, Inc.
• The filing reports a reduction in beneficial ownership percentage due to a 1-for-25 Reverse Stock Split of Galecto, Inc.'s common stock, which was effective on August 29, 2024.
• This reduction also reflects a subsequent increase in the total outstanding shares of Galecto, Inc.
• Novo Holdings A/S now beneficially owns 99,913 shares of Galecto, Inc. Common Stock.
• These 99,913 shares represent approximately 7.6% of Galecto, Inc.'s outstanding shares.
• The percentage is based on 1,316,989 shares of Common Stock outstanding as of October 30, 2024, as reported in Galecto's Form 10-Q filed on November 1, 2024.
• Novo Holdings A/S has sole voting and dispositive power over these 99,913 shares.
• Neither Novo Holdings A/S, the Novo Nordisk Foundation, nor any listed person has effected any transactions in Galecto's Common Shares within the past 60 days.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily a factual disclosure of ownership changes following a corporate action. The continued significant stake by Novo Holdings A/S could be seen as a mild positive, indicating ongoing commitment, but the percentage reduction is a mathematical consequence rather than a strategic divestment.

Positives

• Novo Holdings A/S, a significant life sciences investor, maintains a substantial 7.6% stake in Galecto, Inc., indicating continued long-term interest.
• The filing provides transparency regarding the impact of the reverse stock split and changes in outstanding shares on Novo Holdings A/S's ownership percentage.

Negatives

• The beneficial ownership percentage of Novo Holdings A/S decreased from a prior undisclosed level to 7.6% due to the 1-for-25 reverse stock split and an increase in Galecto's outstanding shares, which dilutes the relative stake.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding Galecto, Inc.'s future performance or Novo Holdings A/S's future investment plans beyond the current ownership disclosure.

Management Comments

• The document does not contain direct quotes or paraphrased statements from Galecto, Inc.'s management. It includes a signature from Barbara Fiorini, General Counsel, Finance & Operations of Novo Holdings A/S, certifying the accuracy of the filing.

Industry Context

This filing reflects a routine ownership update by a major life sciences investor, Novo Holdings A/S, in a biotechnology company, Galecto, Inc. The reverse stock split is a corporate action often undertaken by companies to increase their share price and meet listing requirements, which can impact investor ownership percentages. Novo Holdings' continued significant stake underscores its strategic focus on the life science and biotechnology sector, aligning with its stated investment mandate for development-stage and established companies in this field.

Comparison to Industry Standards

• This Schedule 13D filing is a standard regulatory disclosure for significant ownership changes.
• It does not provide specific financial or operational results of Galecto, Inc. that would allow for a direct comparison to industry-specific benchmarks or comparable companies' project results.
• The document focuses solely on the ownership stake of Novo Holdings A/S in Galecto, Inc. and the impact of a corporate action (reverse stock split) on that stake.

Stakeholder Impact

• Shareholders: Existing shareholders of Galecto, Inc. will see a clearer picture of Novo Holdings A/S's updated ownership stake following the reverse stock split, which may influence investor sentiment regarding institutional backing.
• Galecto, Inc. Management: The continued significant ownership by Novo Holdings A/S, a major life sciences investor, may provide a degree of stability and confidence in the company's long-term prospects.

Key Dates

Recommendation

Keywords

Galecto Inc., Novo Holdings A/S, Novo Nordisk Foundation, Schedule 13D, beneficial ownership, common stock, reverse stock split, biotechnology investment, life sciences investment, SEC filing